Two-Drug Combination Approved for Lung Cancers with BRAF Mutations.
Patients with metastatic non-small cell lung cancer (NSCLC) that has an alteration in the BRAFgene called the V600E mutation can be treated with the FDA approved combination of dabrafenib (Tafinlar®) and trametinib (Mekinist®). The approval is the first specifically for patients with this type of lung cancer, known as BRAF V600E mutation-positive metastatic NSCLC. About 1-2% of lung tumors harbor the V600E mutation, which […]
Two-Drug Combination Approved for Lung Cancers with BRAF Mutations. Read More »
